Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy.
Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy.
复制标题
DOI：
10.1111/cas.13194
复制
发表时间：
2017-04
期刊：
影响因子：
5.7
通讯作者：
Yoshimura A
中科院分区：
文献类型：
--
作者：
Chikuma S;Kanamori M;Mise-Omata S;Yoshimura A
抑制免疫检查点分子PD‐1和CTLA4已被证明是一种很有前途的癌症治疗方法。PD - 1和CTLA4抑制TCR和共刺激信号。第三个T细胞激活信号代表来自细胞因子受体的信号。细胞因子干扰素γ (IFNγ)通过激活细胞毒性T细胞（ctl）在抗肿瘤免疫中发挥重要作用。大多数细胞因子使用Janus kinase (JAK)/signal transducer and activator of transcription （STAT）通路，而细胞因子信号传导抑制因子（SOCS）家族蛋白是JAK/STAT通路的主要负调控因子。在SOCS蛋白中，CIS、SOCS1和SOCS3蛋白可以被认为是第三免疫检查点分子，因为它们调节细胞因子信号，控制CD4+ T细胞的极化和CD8+ T细胞的成熟。本文综述了CIS、SOCS1和SOCS3在抗肿瘤免疫和潜在应用方面的最新进展。
Inhibition of immune checkpoint molecules, PD‐1 and CTLA4, has been shown to be a promising cancer treatment. PD‐1 and CTLA4 inhibit TCR and co‐stimulatory signals. The third T cell activation signal represents the signals from the cytokine receptors. The cytokine interferon‐γ (IFNγ) plays an important role in anti‐tumor immunity by activating cytotoxic T cells (CTLs). Most cytokines use the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, and the suppressors of cytokine signaling (SOCS) family of proteins are major negative regulators of the JAK/STAT pathway. Among SOCS proteins, CIS, SOCS1, and SOCS3 proteins can be considered the third immunocheckpoint molecules since they regulate cytokine signals that control the polarization of CD4+ T cells and the maturation of CD8+ T cells. This review summarizes recent progress on CIS, SOCS1, and SOCS3 in terms of their anti‐tumor immunity and potential applications.